ALNY insider ownership: who sold, why, and what they still hold

What stands out

Routine activity: 63% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.

A share of stake is shown for 0 of the 8 officers and directors who sold. 19 are left out

Left out: Yvonne Greenstreet, Jeffrey Poulton, David Pyott, Tolga Tanguler, Kevin Fitzgerald, Pushkal Garg, Michael Bonney, Bryan Supran, Amy Schulman, Dennis Ausiello, Charles Sigal, Margaret Hamburg, Colleen Reitan, Olivier Brandicourt, Carolyn Bertozzi, Peter Kellogg, Stuart Arbuckle, Melissa McLaughlin and Benjamin Cravatt (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Yvonne Greenstreet

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$20.4M57% planned, 43% to cover taxes

Kevin Fitzgerald

CSO & EVP, Head of Research

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$9.6MDisclosed plan

Pushkal Garg

EVP Chief R&D

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.4M77% planned, 23% to cover taxes

Jeffrey Poulton

EVP, Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$3.2MTo cover taxes

Tolga Tanguler

EVP, Chief Commercial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.4MTo cover taxes

All 8 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

Oct 2, 2026Bryan Supran sold 1.8K shares ($399K) to cover taxes on vesting stock.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Bryan Supran EVP, CLO and Secretary	1,758	$226.88	n/a	n/a	Oct 2, 2026	Oct 6, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the Alnylam Pharmaceuticals, Inc. CEO selling stock?

Yes. Yvonne Greenstreet sold 52K shares ($20.4M) in the past 12 months, 57% of it under a trading plan disclosed in the filings.

Why are Alnylam Pharmaceuticals, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 63% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 37% were to cover taxes. A trading plan schedules sales in advance.

Are any Alnylam Pharmaceuticals, Inc. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold8 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Yvonne Greenstreet Chief Executive Officer, Director	$20.4M 52K shares	Not confirmed share of stake is being verified. Why	57% under a disclosed plan, 43% to cover taxes
Kevin Fitzgerald CSO & EVP, Head of Research	$9.6M 24K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Pushkal Garg EVP Chief R&D	$5.4M 17K shares	Not confirmed share of stake is being verified. Why	77% under a disclosed plan, 23% to cover taxes
Jeffrey Poulton EVP, Chief Financial Officer	$3.2M 9.7K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Tolga Tanguler EVP, Chief Commercial Officer	$2.4M 7.4K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Melissa McLaughlin Chief Human Resources Officer	$1.3M 3.9K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
David Pyott Director	$1.1M 3.8K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Bryan Supran EVP, CLO and Secretary	$399K 1.8K shares	Not confirmed share of stake is being verified. Why	To cover taxes

The full ownership picture0 of 19 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Yvonne Greenstreet

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Yvonne Greenstreet are complete.

Chief Executive Officer, Director

n/a

−52K

n/a

Vesting, gifts, unvested awards and holding lines for Yvonne Greenstreet

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Yvonne Greenstreet are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−1.1Kwithheld by the company for taxes

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
28,141	$151.59	Feb 23, 2031	$2.1M
46,394	$152.61	Mar 1, 2034	$3.4M
36,293	$243.53	Mar 3, 2035	$0
30,425	$325.07	Mar 2, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Jeffrey Poulton

EVP, Chief Financial Officer

n/a

−9.7K

n/a

Vesting, gifts, unvested awards and holding lines for Jeffrey Poulton

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeffrey Poulton are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Some sales match sales reported by Pushkal Garg exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,118	$152.61	Mar 1, 2034	$1.1M
9,800	$243.53	Mar 3, 2035	$0
10,480	$325.07	Mar 2, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

David Pyott

Director

n/a

−3.8K

n/a

Vesting, gifts, unvested awards and holding lines for David Pyott

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Pyott are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,780	$71.99	Jun 1, 2027	$585K
5,228	$151.22	May 16, 2034	$396K
1,558	$258.35	May 8, 2035	$0
1,441	$298.48	May 20, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Tolga Tanguler

EVP, Chief Commercial Officer

n/a

−7.4K

n/a

Vesting, gifts, unvested awards and holding lines for Tolga Tanguler

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Tolga Tanguler are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Some sales match sales reported by Kevin Fitzgerald exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.
Some sales match sales reported by Pushkal Garg exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
9,279	$152.61	Mar 1, 2034	$689K
7,819	$243.53	Mar 3, 2035	$0
10,480	$325.07	Mar 2, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Kevin Fitzgerald

CSO & EVP, Head of Research

n/a

−24K

n/a

Vesting, gifts, unvested awards and holding lines for Kevin Fitzgerald

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kevin Fitzgerald are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Some sales match sales reported by Tolga Tanguler exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
9,000	$119.13	Mar 1, 2028	$970K
2,192	$85.00	Feb 28, 2029	$311K
14,580	$118.05	Feb 26, 2030	$1.6M
839	$119.13	Mar 1, 2028	$90K
20,382	$147.47	Feb 23, 2032	$1.6M
15,692	$151.59	Feb 24, 2031	$1.2M
9,279	$152.61	Mar 1, 2034	$689K
10,352	$190.01	Feb 27, 2033	$382K
7,819	$243.53	Mar 3, 2035	$0
8,105	$325.07	Mar 2, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Pushkal Garg

EVP Chief R&D

n/a

−17K

n/a

Vesting, gifts, unvested awards and holding lines for Pushkal Garg

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Pushkal Garg are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Some sales match sales reported by Jeffrey Poulton exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.
Some sales match sales reported by Tolga Tanguler exactly (date, shares and price). Possibly the same shares reported by both; the filings don't confirm it.

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
9,279	$152.61	Mar 1, 2034	$689K
7,819	$243.53	Mar 3, 2035	$0
10,480	$325.07	Mar 2, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Michael Bonney

Director

n/a

Vesting, gifts, unvested awards and holding lines for Michael Bonney

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Bonney are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,228	$151.22	May 16, 2034	$396K
1,558	$258.35	May 8, 2035	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Bryan Supran

EVP, CLO and Secretary

n/a

−1.8K

n/a

Vesting, gifts, unvested awards and holding lines for Bryan Supran

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bryan Supran are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,381	$325.07	Mar 2, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Amy Schulman

Director

n/a

Vesting, gifts, unvested awards and holding lines for Amy Schulman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Amy Schulman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,228	$151.22	May 16, 2034	$396K
1,558	$258.35	May 8, 2035	$0
1,802	$298.48	May 20, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Dennis Ausiello

Director

n/a

Vesting, gifts, unvested awards and holding lines for Dennis Ausiello

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Dennis Ausiello are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
1,558	$258.35	May 8, 2035	$0
1,441	$298.48	May 20, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Charles Sigal

Director

n/a

Vesting, gifts, unvested awards and holding lines for Charles Sigal

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Charles Sigal are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,228	$151.22	May 16, 2034	$396K
1,558	$258.35	May 8, 2035	$0
1,441	$298.48	May 20, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Margaret Hamburg

Director

n/a

Vesting, gifts, unvested awards and holding lines for Margaret Hamburg

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Margaret Hamburg are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,228	$151.22	May 16, 2034	$396K
1,558	$258.35	May 8, 2035	$0
1,441	$298.48	May 20, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Colleen Reitan

Director

n/a

Vesting, gifts, unvested awards and holding lines for Colleen Reitan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Colleen Reitan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,228	$151.22	May 16, 2034	$396K
1,558	$258.35	May 8, 2035	$0
1,441	$298.48	May 20, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Olivier Brandicourt

Director

n/a

Vesting, gifts, unvested awards and holding lines for Olivier Brandicourt

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Olivier Brandicourt are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,228	$151.22	May 16, 2034	$396K
1,558	$258.35	May 8, 2035	$0
1,441	$298.48	May 20, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Carolyn Bertozzi

Director

n/a

Vesting, gifts, unvested awards and holding lines for Carolyn Bertozzi

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Carolyn Bertozzi are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,228	$151.22	May 16, 2034	$396K
1,558	$258.35	May 8, 2035	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Peter Kellogg

Director

n/a

Vesting, gifts, unvested awards and holding lines for Peter Kellogg

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Peter Kellogg are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,228	$151.22	May 16, 2034	$396K
1,558	$258.35	May 8, 2035	$0
1,441	$298.48	May 20, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Stuart Arbuckle

Director

n/a

Vesting, gifts, unvested awards and holding lines for Stuart Arbuckle

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Stuart Arbuckle are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,279	$397.83	Jan 5, 2036	$0
1,441	$298.48	May 20, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Melissa McLaughlin

Chief Human Resources Officer

n/a

−3.9K

n/a

Vesting, gifts, unvested awards and holding lines for Melissa McLaughlin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Melissa McLaughlin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
3,567	$325.07	Mar 2, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Benjamin Cravatt

Director

n/a

Vesting, gifts, unvested awards and holding lines for Benjamin Cravatt

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Benjamin Cravatt are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
4,393	$295.63	Jun 1, 2036	$0

Estimate: options held × ($226.88 − strike price), using the most recent insider trade price on Form 4 (Oct 2, 2026), not a market close.

Holdings and share of stake for Alnylam Pharmaceuticals, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$44.0M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $44.0M across 119,540 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $27.9M · 63%

37%

The lighter segment is sales with no plan disclosed in the filing ($16.1M), including tax-related sales outside a plan.

Taxes

$19.8M of sales (45.1%) cite tax obligations in their footnotes, $3.7M of them also under a plan. Separately, 1,121 shares ($499K) were withheld by the company for taxes, which isn't a market sale. Example: Bryan Supran, Oct 2, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Yvonne Greenstreet Chief Executive Officer, Director	52K	$20.4M	57%	46%	Nov 12, 2025 to Mar 4, 2026
Kevin Fitzgerald CSO & EVP, Head of Research	24K	$9.6M	100%	22%	Nov 17, 2025 to Mar 5, 2026
Pushkal Garg EVP Chief R&D	17K	$5.4M	77%	12%	Jan 12, 2026 to Mar 5, 2026
Jeffrey Poulton EVP, Chief Financial Officer	9.7K	$3.2M	0%	7%	Jan 12, 2026 to Mar 4, 2026
Tolga Tanguler EVP, Chief Commercial Officer	7.4K	$2.4M	0%	6%	Jan 12, 2026 to Mar 4, 2026
Melissa McLaughlin Chief Human Resources Officer	3.9K	$1.3M	100%	3%	Apr 2, 2026 to Apr 6, 2026
David Pyott Director	3.8K	$1.1M	100%	3%	Jun 1, 2026 to Jun 1, 2026
Bryan Supran EVP, CLO and Secretary	1.8K	$399K	0%	0.9%	Oct 2, 2026 to Oct 2, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$17.1M	$17.1M	$0	$0
Dec 2025	$0	$0	$0	$0
Jan 2026	$7.0M	$1.4M	$5.6M	$0
Feb 2026	$7.0M	$2.8M	$4.2M	$0
Mar 2026	$10.1M	$4.1M	$6.0M	$0
Apr 2026	$1.3M	$1.3M	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$1.1M	$1.1M	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$0	$0	$0	$0
Oct 2026	$399K	$0	$399K	$0

Is this normal? Selling year by year5 earlier years to compare with

Less than usual: about half of the 5-year average. 8 insiders sold; the average is 8 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	120K	8	$44.0M
Oct 16, 2025 1 year earlier	284K	10	$97.2M
Oct 16, 2024 2 years earlier	234K	11	$50.2M
Oct 17, 2023 3 years earlier	131K	8	$27.1M
Oct 17, 2022 4 years earlier	121K	5	$22.2M
Oct 17, 2021 5 years earlier	313K	6	$50.5M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty19 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Alnylam Pharmaceuticals, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology910 filings on record, 48 filed in the 12-month period, and how we read them

All 910 Forms 3, 4 and 5 on record for Alnylam Pharmaceuticals, Inc. (SEC CIK 1178670), filed from May 27, 2004 to Oct 6, 2026; 48 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages. 22 filings were left out because Alnylam Pharmaceuticals, Inc. filed them as an owner of another company's stock.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (45)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Robert Hesslein	Mar 5, 2025	8,002 shares, last reported balance as of Mar 3, 2025
Phillip Sharp	Jan 24, 2025	645,633 shares, last reported balance as of Jan 23, 2025
Indrani Franchini	Feb 29, 2024	4,133 shares, last reported balance as of Feb 28, 2024
Akshay Vaishnaw	Aug 7, 2023	23,289 shares, last reported balance as of Aug 4, 2023
Marsha Fanucci	May 19, 2023	136 shares, last reported balance as of Feb 23, 2023
Steven Paul	Apr 5, 2022	1,000 shares, last reported balance as of Apr 1, 2022
John Maraganore	Dec 23, 2021	230,796 shares, last reported balance as of Dec 22, 2021
Laurie Keating	Aug 9, 2021	5,566 shares, last reported balance as of Aug 5, 2021
Barry Greene	Sep 11, 2020	76,987 shares, last reported balance as of Sep 9, 2020
Paul Schimmel	Jul 2, 2019	306,996 shares, last reported balance as of Mar 13, 2018
Manmeet Soni	Mar 1, 2019	83 shares, last reported balance as of Jul 10, 2018
Michael Mason	Sep 28, 2018	839 shares, last reported balance as of Aug 13, 2018
John Clarke	Jun 22, 2018	2,100,759 shares, last reported balance as of May 31, 2018
John Clarke	Jun 22, 2018	8,891 shares, last reported balance as of May 21, 2014
Kevin Starr	Jun 6, 2017	No balance on record
Sanofi	Jun 1, 2017	10,554,134 shares, last reported balance as of May 31, 2017
David-Alexandre Gros	Dec 22, 2016	1,000 shares, last reported balance as of Feb 22, 2016
Laurence Reid	Jan 5, 2015	19,869 shares, last reported balance as of Dec 31, 2014
Victor Dzau	Jun 10, 2013	No balance on record
NOVARTIS AG	Sep 24, 2012	4,051,002 shares, last reported balance as of Sep 20, 2012
Patricia Allen	Dec 10, 2010	1,165 shares, last reported balance as of Dec 8, 2010
Kenneth Koblan	Dec 10, 2010	357 shares, last reported balance as of Dec 8, 2010
James Vincent	Jun 18, 2010	No balance on record
Vicki Sato	Jun 4, 2010	No balance on record
Edward Scolnick	Jun 12, 2009	No balance on record
John Schmidt Jr.	Dec 11, 2008	No balance on record
Peter Barrett	Jun 16, 2006	328,877 shares, last reported balance as of Mar 7, 2006
Peter Barrett	Jun 16, 2006	2,979,807 shares, last reported balance as of Mar 7, 2006
ATLAS VENTURE FUND V LP	Feb 27, 2006	3,354,250 shares, last reported balance as of Feb 24, 2006
Vincent Miles	Dec 9, 2005	No balance on record
John Berriman	Jun 10, 2005	2,475 shares, last reported balance as of May 27, 2004
Abingworth Management LTD	Mar 15, 2005	3,778,522 shares, last reported balance as of May 27, 2005
POLARIS VENTURE MANAGEMENT CO III LLC	Feb 24, 2005	2,018,992 shares, last reported balance as of Feb 2, 2005
Christoph Westphal	Jun 7, 2004	2,714,803 shares, last reported balance as of Jun 3, 2004
Christoph Westphal	Jun 7, 2004	100,557 shares, last reported balance as of Jun 3, 2004
ARCH VENTURE FUND V LP	Jun 1, 2004	222,500 shares, last reported balance as of May 27, 2004
Clinton Bybee	Jun 1, 2004	222,500 shares, last reported balance as of May 27, 2004
ARCH V ENTREPRENEURS FUND LP	Jun 1, 2004	222,500 shares, last reported balance as of May 27, 2004
Keith Crandell	Jun 1, 2004	222,500 shares, last reported balance as of May 27, 2004
ARCH VENTURE PARTNERS V LP	Jun 1, 2004	222,500 shares, last reported balance as of May 27, 2004
Robert Nelsen	Jun 1, 2004	222,500 shares, last reported balance as of May 27, 2004
Steven Lazarus	Jun 1, 2004	222,500 shares, last reported balance as of May 27, 2004
ARCH VENTURE PARTNERS V LLC	Jun 1, 2004	222,500 shares, last reported balance as of May 27, 2004
CHP II LP	Jun 1, 2004	232,500 shares, last reported balance as of May 27, 2004
Thomas Ulich	May 27, 2004	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Alnylam Pharmaceuticals, Inc. insiders sold $44.0M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Alnylam Pharmaceuticals, Inc. CEO selling stock?

Why are Alnylam Pharmaceuticals, Inc. insiders selling?

Are any Alnylam Pharmaceuticals, Inc. insiders buying?

The evidence

Taxes

Sales by month